User:Brian Boyle/Sandbox 1: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 6: Line 6:
   
   
== '''PZP Domain''' ==
== '''PZP Domain''' ==
The PZP domain of BRPF1 is located at its N-terminus and has been shown to <scene name='91/910741/Pzp_with_h3/2'>associate with the histone H3 tail</scene> <ref name="Klein" />. Three residues in the H3 peptide undergo unique interactions with the binding pocket. These are <scene name='91/910741/H3_ala_1/1'>Ala-1</scene>, <scene name='91/910741/Arg_2/1'>Arg-2</scene>, and Thr-3.<ref name="Klein" />. In addition to its binding to the histone H3 N-terminus, the PZP domain can associate non-specifically with DNA. It is thought that this interaction is mediated by lys-383, lys-390, and arg-392<ref name="Klein" />. These residues form a positively charged patch in the second PHD finger that can interact with the negative DNA backbone. Interestingly, the DNA- and histone H3-binding capabilities of the PZP domain seem to work in tandem, as is associates much stronger with the nucleosome core particle than it does with the H3 tail alone<ref name="Klein_2015">PMID:26626149</ref>.
The PZP domain of BRPF1 is located at its N-terminus and has been shown to <scene name='91/910741/Pzp_with_h3/2'>associate with the histone H3 tail</scene> <ref name="Klein" />. Three residues in the H3 peptide undergo unique interactions with the binding pocket. These are <scene name='91/910741/H3_ala_1/1'>Ala-1</scene>, <scene name='91/910741/Arg_2/1'>Arg-2</scene>, and Thr-3.<ref name="Klein" />. In addition to its binding to the histone H3 N-terminus, the PZP domain can associate non-specifically with DNA. It is thought that this interaction is mediated by lys-383, lys-390, and arg-392<ref name="Klein" />. These residues form a <scene name='91/910741/Positive_patch_pzp/1'>positively charged patch</scene> in the second PHD finger that can interact with the negative DNA backbone. Interestingly, the DNA- and histone H3-binding capabilities of the PZP domain seem to work in tandem, as is associates much stronger with the nucleosome core particle than it does with the H3 tail alone<ref name="Klein_2015">PMID:26626149</ref>.


== '''Bromodomain Structure & Acetyllysine Recognition''' ==
== '''Bromodomain Structure & Acetyllysine Recognition''' ==

Revision as of 02:15, 4 May 2022

Apo BRPF1 Bromodomain solved via solution NMR. (PDB entry 2d9e)

Drag the structure with the mouse to rotate

BRPF1 Association with the MOZ HAT Complex

The MOZ Histone Acetyltransferase Complex is a tetramer consisting of MEAF6, ING5, BRPF1 and MOZ or MORF[1]. Within BRPF1, there are two non-chromatin-binding modules surrounding the PZP domain that are responsible for its association with the MOZ HAT Complex. On the N-terminal side of the PZP, lies the MOZ/MORF binding domain[2]. On the other side of the PZP domain, there is a small module involved in binding to ING5 and MEAF6[3]. BRPF1 seems to be required for the formation of the MOZ HAT complex, as it acts as a bridge associating MOZ or MORF with ING5 and MEAF6[3].

Evolutionary Relationships

Bromodomains are categorized into several families based on sequence and structural similarity. The BRPF1 bromodomain belongs to family IV of bromodomains[4].

Links to Human Disease

BRPF1 has been implicated in the progression of several cancers. Chromosomal translocations of the gene encoding MOZ (a subunit in the MOZ HAT complex) have been linked to the development of acute myeloid leukemia [5]. The crucial role of BRPF1 in this complex has made it the subject of many studies in order to understand how this mutation leads to a cancer phenotype. Another study reported an association between upregulation of the BRPF1 gene and poor survival rates in hepatocellular carcinoma patients [6].

Mutations within the gene itself have been associated with neurological disorders and widespread reduced histone acetylation [7].

Available Structures

References

  1. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named Klein
  2. ↑ Lalonde ME, Avvakumov N, Glass KC, Joncas FH, Saksouk N, Holliday M, Paquet E, Yan K, Tong Q, Klein BJ, Tan S, Yang XJ, Kutateladze TG, Cote J. Exchange of associated factors directs a switch in HBO1 acetyltransferase histone tail specificity. Genes Dev. 2013 Sep 15;27(18):2009-24. doi: 10.1101/gad.223396.113. PMID:24065767 doi:https://dx.doi.org/10.1101/gad.223396.113
  3. ↑ 3.0 3.1 Ullah M, Pelletier N, Xiao L, Zhao SP, Wang K, Degerny C, Tahmasebi S, Cayrou C, Doyon Y, Goh SL, Champagne N, Cote J, Yang XJ. Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes. Mol Cell Biol. 2008 Nov;28(22):6828-43. doi: 10.1128/MCB.01297-08. Epub 2008 Sep , 15. PMID:18794358 doi:10.1128/MCB.01297-08
  4. ↑ Lloyd JT, Glass KC. Biological function and histone recognition of family IV bromodomain-containing proteins. J Cell Physiol. 2018 Mar;233(3):1877-1886. doi: 10.1002/jcp.26010. Epub 2017 Jun , 13. PMID:28500727 doi:https://dx.doi.org/10.1002/jcp.26010
  5. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named Obi
  6. ↑ Cheng CL, Tsang FH, Wei L, Chen M, Chin DW, Shen J, Law CT, Lee D, Wong CC, Ng IO, Wong CM. Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer. Commun Biol. 2021 Jul 20;4(1):888. doi: 10.1038/s42003-021-02405-6. PMID:34285329 doi:https://dx.doi.org/10.1038/s42003-021-02405-6
  7. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named Yan

Proteopedia Page Contributors and Editors (what is this?)

Brian Boyle